Bush Jennifer 4

What Happened

• Jennifer Bush, Chief Operating Officer and Chief Legal Officer of Artiva Biotherapeutics (ARTV), sold 8,790 shares on 2026-05-19 in an open-market/private sale, generating roughly $79,179 (8,790 × $9.01).
• This was a sale (S) reported as automatic sell-to-cover for tax withholding related to the vesting/release of restricted stock units, not a discretionary market-timing trade.

Key Details

• Transaction date: 2026-05-19.
• Price: reported weighted average sale price $9.0078; reported price range $8.7439–$9.0104. The line-item value shown: $79,179.
• Shares owned after transaction: not specified in the provided filing excerpt.
• Footnotes: F1 — sale was automatic under the issuer’s sell-to-cover policy to satisfy tax withholding on RSU vesting; F2 — weighted-average and price range provided, with full per-price breakdown available on request.
• Filing timeliness: Report lists the period and filing date as 2026-05-19, indicating a same‑day/timely report.

Context

• Sell-to-cover transactions are routine administrative sales to satisfy tax obligations when restricted stock units vest; they are common among executives and do not, by themselves, indicate a change in insider sentiment.
• Purchases are generally more informative about confidence in the company; this filing documents tax-related share disposal only.